

## REVIEW ARTICLE

# Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate

TA Luger\*

Clinic and Polyclinic of Dermatology, University of Münster, Münster, Germany

\*Correspondence: TA Luger. E-mail: luger@uni-muenster.de

## Abstract

Although emollients can be sufficient to manage mild atopic dermatitis (AD), acute flares resulting in moderate-to-severe symptoms require treatment with anti-inflammatory agents, such as topical corticosteroids (TCs) and topical calcineurin inhibitors (TCIs). This review examines the role of a member of the newest class of TCs, the fourth-generation compound methylprednisolone aceponate (MPA) in AD management, with reference to the chemical structure, pharmacokinetics, efficacy in AD, safety assessed in preclinical and clinical trials and dosing considerations. MPA has an optimized efficacy/safety profile with minimal local or systemic adverse effects. In addition, it offers the opportunity for once-daily dosing, which provides benefits in terms of patient compliance with treatment.

Received: 30 March 2010; Accepted: 11 June 2010

## Keywords

anti-inflammatory agents, atopic, corticosteroids, dermatitis, eczema, emollients

## Conflicts of interest

In the past 3 years I have been paid as a consultant by a company with a vested interest in the product being studied, on issues related and unrelated to the product being studied.

## Funding sources

Preparation of this manuscript was supported financially by Intendis GmbH.

## Introduction

### Background

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease characterized by dry skin (xerosis) and increased trans-epidermal water loss caused by breakdown of the skin's normal barrier function. A key symptom is itching; in the acute phase erythema, papules, vesicles, crusts, weeping and oedema can be present, while thickening, lichenification and scaling of the skin are characteristic of the chronic phase.


Emollients form the basis of treatment for acute and chronic AD, but most patients also require anti-inflammatory therapy with either topical corticosteroids (TCs) or topical calcineurin inhibitors (TCIs) for management of acute flares. TCs have remained the gold standard anti-inflammatory treatment since the introduction of hydrocortisone, the first TC, in the 1950s. Adaptations to the basic molecular structure have been made to optimize the

anti-inflammatory and immunosuppressive capacities of TCs, while minimizing unwanted adverse effects. Balance between efficacy, potency and safety remains a key therapeutic goal. This review examines the properties and role of a member of the newest class of TCs, the fourth-generation compound methylprednisolone aceponate (MPA) in AD management.

### The use of emollients and anti-inflammatory agents in treatment of AD

Routine use of emollients is the basis of treatment for AD. Ointments, fatty ointments, lipocreams, creams and lotions soothe irritation, rehydrate the skin and help to keep the skin barrier intact (Fig. 1).

Ointments have a high ratio of fat to water and do not require the addition of (potentially allergenic) preservatives. They are most efficient in keeping the skin hydrated.<sup>1</sup> Creams contain a higher proportion of water than ointments, making them easier to



**Figure 1** Use of emollients should be tailored to the skin type of the affected area.

spread, and can be applied liberally and frequently. Lotions have the highest water content of any emollient and therefore are rapidly absorbed. While they can soothe irritation rapidly, they are less efficient as moisturizers.

Emollients can be sufficient for the management of mild AD, but acute flares resulting in moderate-to-severe symptoms require treatment with anti-inflammatory agents (Fig. 2). TCs have remained the gold standard of anti-inflammatory therapy in AD for more than 50 years, even after the introduction of the TCIs (pimecrolimus and tacrolimus) for mild-to-moderate cases. TCs induce their effects via several mechanisms, including effects on gene expression and on the cells of the immune system. Whilst it is recognized that management of AD commonly requires concomitant use of emollients and anti-inflammatory agents,<sup>2</sup> recent research has confirmed that, in children with AD, continued use of emollients after treatment with corticosteroids has ceased can help to maintain clinical improvements in xerosis and itching.<sup>3</sup>

The choice of vehicle used for TCs is important. Ideally, the selected vehicle should enhance lipophilicity and/or hydrate the stratum corneum to optimize absorption by the skin and facilitate release of the active ingredient into keratinocytes. These attributes increase the bioavailability of the topical therapy and can influence the tolerability and ease of application of a TC.<sup>4</sup> For instance, stiff, occlusive ointments are unsuitable for application to weeping skin,

but are suitable for application to the soles of the feet; creams are the vehicle of choice for acute and sub-acute dermatoses in moist or intertriginous areas.<sup>5</sup>


**Optimizing corticosteroid structure for use in AD**

Many variants of the basic steroid structure (seventeen carbon atoms in four fused rings, with further carbon atoms contained in side chains) have been produced in an attempt to improve absorption, efficacy and potency, while minimizing side-effects (Table 1).

Such modifications can increase intrinsic potency (e.g. by methylation at C-6 or halogenation at C-9), improve lipophilicity (by esterification of alcohol residues) and increase metabolic resistance.<sup>6-8</sup> Modifications that dramatically affect potency can often be accompanied by an increase in adverse events, however.<sup>7,8</sup> Researchers have sought to optimize the balance between potency and safety of TCs – this is particularly important in patients with chronic AD, and in paediatric patients. Corticosteroids are classified according to potency; the British classification scheme has four groups while the American scheme uses seven.<sup>9</sup> Table 1 shows the potency ranking of TCs based on the British scheme. A relatively small group of compounds combine optimum efficacy with minimum side-effects (Fig. 3). Newer molecules – e.g. mometasone furoate (MM), hydrocortisone-17-butyrate-21-propionate, prednicarbate and MPA – demonstrate favourable risk-benefit ratios with respect to anti-inflammatory effects, acceptability and convenience for patients, weak atrophogenicity and lack of cross-sensitivity reactions.<sup>7,10</sup>

**Mode of action of TCs in AD**

Corticosteroids act via a number of pathways to reduce inflammation.<sup>11,12</sup> Firstly, they exert differential control of gene expression via activation of nuclear receptors in target cells, which then regulate gene transcription.<sup>13,14</sup> On entering T lymphocytes, for instance, the drug molecule binds to specific glucocorticoid




**Figure 2** Stepwise management of AD. Treatment should be escalated according to the severity of AD symptoms. AD, atopic dermatitis; CyA, cyclosporin A; PUVA, psoralen and UVA treatment; TCs, topical corticosteroids; TCIs, topical calcineurin inhibitors. Reproduced from Akdis *et al.*<sup>2</sup>

**Table 1** Structure and potency of some corticosteroid preparations used in AD

Corticosteroid	Structural modifications	Formulations
<b>Very potent</b>		
Betamethasone dipropionate	6 $\alpha$ -methyl; 9 $\alpha$ -chloro; 16 $\beta$ -methyl; 17,21-dipropionate	Ointment (0.05%); cream (0.05%)
Clobetasol propionate	6 $\alpha$ -methyl; 9 $\alpha$ -fluoro; 16 $\beta$ -methyl; 17-propionate	Ointment (0.05%); cream (0.05%)
Diflorasone diacetate	6 $\alpha$ -fluoro; 9 $\alpha$ -fluoro; 16 $\beta$ -methyl; 17,21-diacetate	Ointment (0.05%)
Halobetasol propionate	6 $\alpha$ -fluoro; 9 $\alpha$ -fluoro; 16 $\beta$ -methyl; 17-propionate; 21-chloro	Cream (0.05%)
<b>Potent</b>		
Amcinomide		Ointment (0.1%); lotion (0.1%)
Betamethasone valerate	6 $\alpha$ -methyl; 9 $\alpha$ -fluoro; 16 $\beta$ -methyl; 17-valerate	Ointment (0.01%)
Desoxymethasone	9 $\alpha$ -fluoro; 16 $\alpha$ -methyl	Ointment (0.25%); cream (0.25%); gel (0.05%)
Diflorasone diacetate	6 $\alpha$ -fluoro; 9 $\alpha$ -fluoro; 16 $\beta$ -methyl; 17,21-diacetate	Ointment (0.05%); cream (0.05%)
Fluocortolone		Cream (0.25%)
Fluocinonide	6 $\alpha$ -fluoro; 9 $\alpha$ -fluoro; 16,17-acetonide; 21-acetate	Ointment (0.05%); cream (0.05%); gel (0.05%)
Fluticasone propionate	6,9 $\alpha$ -difluoro; 11 $\beta$ -hydroxy; 16 $\alpha$ -methyl-3oxo; 17 $\beta$ -carbothioate	Ointment (0.005%)
Halcinonide	9 $\alpha$ -fluoro; 16,17-acetonide; 21-chloro	Ointment (0.1%); cream (0.1%)
Methylprednisolone aceponate	6 $\alpha$ -methyl; 17-propionate; 21-acetate	Ointment (0.1%), cream (0.1%), milk (0.1%)
Mometasone furoate	9 $\alpha$ -fluoro; 16 $\alpha$ -methyl; 17-furoate; 21-chloro	Ointment (0.1%)
Triamcinolone acetonide	9 $\alpha$ -fluoro; 16,17-acetonide	Ointment (0.5%, 0.1%); cream (0.5%)
<b>Moderately potent</b>		
Betamethasone dipropionate	6 $\alpha$ -methyl; 9 $\alpha$ -chloro; 16 $\beta$ -methyl; 17,21-dipropionate	Lotion (0.05%)
Betamethasone valerate	6 $\alpha$ -methyl; 9 $\alpha$ -chloro; 16 $\beta$ -methyl; 17-valerate	Cream (0.01%); lotion (0.01%)
Desoxymethasone	9 $\alpha$ -fluoro; 16 $\alpha$ -methyl	Cream (0.05%); gel (0.05%)
Fluocinolone acetonide	6 $\alpha$ -fluoro; 9 $\alpha$ -fluoro; 16,17-acetonide	Ointment (0.025%); cream (0.2%, 0.025%); oil (0.01%)
Flurandrenolide	6 $\alpha$ -methyl; 6 $\alpha$ -fluoro; 11,21 dihydroxy; 16,17-(1-methylethylidene)bis-oxy	Ointment (0.05%); cream (0.05%)
Fluticasone propionate	6,9 $\alpha$ -difluoro; 11 $\beta$ -hydroxy; 16 $\alpha$ -methyl-3oxo; 17 $\beta$ -carbothioate	Cream (0.05%)
Halcinonide	9 $\alpha$ -fluoro; 16,17-acetonide; 21-chloro	Ointment (0.1%); cream (0.1%)
Hydrocortisone butyrate	17-butyrate	Cream (0.1%)
Hydrocortisone valerate	17-valerate	Cream (0.025%)
Mometasone furoate	9 $\alpha$ -fluoro; 16 $\alpha$ -methyl; 17-furoate; 21-chloro	Cream (0.1%)
Triamcinolone acetonide	9 $\alpha$ -fluoro; 16,17-acetonide	Ointment (0.1%); lotion (0.1%)
<b>Less potent</b>		
Alclometasone dipropionate	7 $\alpha$ -chloro; 16 $\alpha$ -methyl; 17,21-dipropionate	Ointment (0.05%); cream (0.05%)
Betamethasone valerate	6 $\alpha$ -methyl; 9 $\alpha$ -chloro; 16 $\beta$ -methyl; 17-valerate	Lotion (0.05%)
Desonide	16,17-(1-methylidene)bis(oxy)-pregna-1,4-diene-3; 20-dione	Cream (0.05%)
Dexamethasone	9 $\alpha$ -fluoro; 16 $\alpha$ -methyl	Cream (0.1%)
Fluocinolone acetonide	6 $\alpha$ -fluoro; 9 $\alpha$ -fluoro; 16,17-acetonide	Cream (0.01%); solution (0.01%)
Methylprednisolone	6 $\alpha$ -methyl	Cream (1%)
Prednicarbate	17-ethylcarbonate; 21-propionate	Cream (0.1%)
Triamcinolone acetonide	9 $\alpha$ -fluoro; 16,17-acetonide	Cream (0.1%)

Adapted from Hengge et al., 2006<sup>5</sup> and Brazzini, 2002<sup>7</sup>.



**Figure 3** Efficacy versus side-effects of corticosteroids. A representation of efficacy versus adverse events [therapeutic index (TIX)] for a number of topical corticosteroids. The clinical compounds (PC, MM, MPA, HCB) have a TIX of 2.0 indicating a very favourable efficacy to adverse events rate. BMV, betamethasone valerate; CP, clobetasol propionate; HCB, hydrocortisone butyrate; PC, prednicarbate; HPA, hypothalamic-pituitary-adrenal; MM, mometasone furoate; MPA, methylprednisolone aceponate; HC, halcinonide; TRI, triamcinolone acetonide. Adapted from Luger *et al.*<sup>10</sup>

receptors (GR) in the cytoplasm to form a complex which then translocates to the cell nucleus and binds to specific DNA-responsive elements. The end result is downregulation of production of pro-inflammatory cytokines such as tumour necrosis factor  $\alpha$  (TNF $\alpha$ ), interleukin-1 $\alpha$  (IL-1 $\alpha$ ), IL-3, IL-5, granulocyte-macrophage colony stimulating factor and upregulation of other molecules including annexin 1.<sup>7,9,12,13,15,16</sup> Increased concentrations of the proinflammatory cytokines IL-1 $\beta$ , IL-6 and TNF $\alpha$  in the cytoplasm sensitize the GR, increasing the rate of corticosteroid binding.<sup>17</sup> Secondly, corticosteroids also reduce inflammation by reducing synthesis of pro-inflammatory mediators such as prostaglandins and leukotrienes.<sup>18</sup>

The overall effect of corticosteroid treatment is to suppress the release of arachidonic acid,<sup>19</sup> impair the function and maturation of dendritic cells,<sup>20,21</sup> inhibit the migration of leucocytes to sites of inflammation,<sup>7</sup> suppress eosinophil maturation,<sup>22</sup> diminish microvascular leakage in inflamed skin,<sup>23</sup> and reduce collagen synthesis.<sup>24</sup>

### Adverse effects of TCs

The most common adverse effects of corticosteroids are local. Rarely, absorption of corticosteroids into the systemic circulation can give rise to systemic effects,<sup>25</sup> reflecting the fact that their mode of action is non-specific.

Local adverse effects result mainly from mineralocorticoid anti-proliferative effects on keratinocytes and fibroblasts, leading to epidermal and dermal thinning.<sup>26</sup> Treatment with TCs may also

inhibit epidermal lipid synthesis as well as lipid layer formation and alter stratum corneum integrity, resulting in an impaired epidermal barrier function.<sup>27,28</sup> However, disturbed epidermal expression of involucrin, loricrin, filaggrin and keratins in patients with AD was improved upon treatment with TCs.<sup>28</sup>

Changes in gene transcription can lead to adverse events, mainly related to actions on electrolyte and water balance; neoglycogenesis and tissue repair; and inhibition of adenohipophyseal function.<sup>7,13</sup> Concern about serious adverse events associated with corticosteroids can lead in some cases to 'corticosteroid phobia'.<sup>29</sup>

Skin atrophy, evidenced by thinning of the skin and the presence of telangiectasias and striae in areas of dermis subject to mechanical stress,<sup>5,9,17</sup> is, perhaps the best known adverse event associated with TC use. Inhibition of the pituitary-adrenal axis is the most serious.<sup>17,30</sup> Atrophy involves epidermal, dermal and sub-cutaneous tissue and is caused by changed viscoelasticity in those glycoproteins and proteoglycans responsible for interfibrillar adhesion of collagen.<sup>9,17,31</sup> These changes can occur after a few months of topical therapy and also contribute to the widening of blood vessels.<sup>7</sup> Epidermal thinning is caused by a reduction in cell size and is in part reversible. This is not always true of atrophy in deeper skin layers.<sup>32</sup> Striae represent a permanent type of skin atrophy and consist of visible, scar tissue.<sup>5</sup> From the patient perspective, they are, therefore, an important local adverse event associated with long-term TC use, particularly when they occur in highly visible areas.<sup>33</sup>


Small numbers of patients experience either hypersensitivity or resistance to corticosteroids – probably as a result of mutations in the GR.<sup>9,30</sup> Perioral dermatitis, tinea incognita, corticoid acne, rosacea, hypertrichosis and hypopigmentation are distressing to patients and can affect compliance. 'Steroid face' is a term used to describe erythema, telangiectasia and rosacea-like symptoms that may develop after prolonged treatment of facial AD. Corticosteroids probably induce degeneration of the follicular epithelium, causing exit of follicular contents.<sup>7</sup>

The most recent generation of corticosteroids – the non-halogenated corticosteroid diesters – balances potent anti-inflammatory activity with reduced systemic toxicity and weak atrophogenicity.<sup>7,34</sup> The remainder of this review concentrates on one member of this group, MPA.

### Use of MPA in AD

#### Adaptation of chemical structure to meet the needs of patients

As shown in Fig. 4, MPA has a methyl group at C-6 and both of the alcohol residues attached to the five-membered ring are esterified (a propionate group at C-17 and an acetate group at C-21). Methylation at C-6 increases receptor binding – and therefore potency – while double esterification significantly increases lipophilicity, facilitating rapid and efficient penetration of the stratum corneum and increased bioavailability.<sup>35,36</sup> Unlike other potent



**Figure 4** Structures of prednisolone and methylprednisolone aceponate.

corticosteroids, MPA does not contain a halogen at C-9; this contributes to a high degree of dissociation between topical and systemic activity.<sup>36</sup>

MPA is metabolized rapidly by esterases within the epidermis and dermis. Under physiological conditions, the acetate group is preferentially removed to produce the key metabolite methylprednisolone-17-propionate (MPP), which binds three times more strongly to the GR than does MPA.<sup>35,36</sup> This local activation process has been shown to take place more rapidly in inflamed skin than in normal skin, because of the increased concentrations of esterases and therefore the active metabolite is concentrated in damaged skin.<sup>31</sup> MPP undergoes a rearrangement (acyl migration) of the propionate group from C-17 to C-21, forming methylprednisolone-21-propionate. Once in the skin, methylprednisolone-21-propionate is easily hydrolysed and rendered relatively inactive. Any MPP entering the systemic circulation is rapidly inactivated by conjugation with glucuronic acid, reducing the potential for systemic side-effects.<sup>37</sup>

#### Efficacy of MPA in AD

The onset of activity of MPA is very rapid. A majority of AD patients (50–80%) experience complete or distinct improvement in objective (erythema, vesiculation, weeping, crusting, scaling and lichenification) and subjective (itching, burning and pain)

symptoms within 1 week of treatment according to patients' and physicians' global assessments.<sup>38,39</sup> This proportion improves to >90% of patients with longer (up to 3 weeks) treatment.<sup>37,38,40</sup> In particular, MPA provides fast and effective relief from itching and reddening, especially in patients with severe symptoms.<sup>39</sup>

Once-daily MPA has demonstrated good efficacy, with rapid onset of activity in a wide range of patients with AD.<sup>41–43</sup> In infants aged <18 months, 85% treated with a milk formulation of MPA experienced complete remission or significant improvement of AD after 3 weeks.<sup>41</sup> Vesiculation was completely absent after 1 week of treatment and no patient had exudation after 3 weeks.<sup>41</sup> More than 90% of patients with AD on the hairy part of the scalp experienced complete remission or significant improvement in symptoms (patients' and physicians' global assessment) after ~2 weeks' treatment with once-daily MPA (0.1%) solution.<sup>43</sup> Among patients with severe AD flares, 67% of patients were clear of or experienced significant improvement in symptoms (according to Investigator's Global Assessment) after 3 weeks of treatment with MPA 0.1% ointment applied once daily, the same percentage as in patients treated with tacrolimus 0.03% ointment twice daily.<sup>42</sup> A notable ~70% improvement [mean visual analogue scale score (VAS)] in itching was reported after 7 days' treatment, which was reflected in better quality of sleep and a 90% improvement in Eczema Area and Severity Index (EASI) scores by end of treatment. Indeed, MPA was superior to tacrolimus in terms of itching, EASI score and sleep quality.<sup>42</sup> The authors of this study therefore concluded that these advantages recommended the use of MPA as first line treatment in AD. Patients who recovered from AD flares had a 3.5-fold lower risk of relapse with maintenance therapy of twice-daily emollient applications plus MPA (0.1%) ointment (applied once daily at weekends only) than with emollient alone.<sup>44</sup> During 16 weeks of maintenance therapy with MPA, small increases in VAS for intensity of itching (~5 mm) and EASI (~0.5 points) were recorded, but no signs of skin atrophy were observed and no other adverse events were reported.<sup>44</sup> A similar study with intermittent tacrolimus treatment in children with AD also indicated that maintenance therapy can reduce the incidence of flares<sup>45</sup> – this is significant because tacrolimus is not universally licensed for continuous use because of concerns over its long-term safety. Two of 59 children in the study did experience serious immunosuppression-related events; however, more work would be required to address the concerns raised in the US FDA's black box warning for tacrolimus (see <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm151161.htm>).

In healthy volunteers, a comparison of MPA with MM confirmed that, while both fourth-generation TCs were equally effective in reducing UVB light-induced skin erythema, there were important differences in safety parameters. Atrophogenicity, incidence and severity of telangiectasia and incidence of serum cortisol level suppression were all markedly higher with MM.<sup>46</sup>

### Once-daily application

Most topical anti-inflammatory medications for AD are applied twice daily. The safety (see below) and efficacy of MPA permit once-daily administration.<sup>36,38,40,42,47,48</sup> As routine skin care products (such as emollients, oils, moisturizers) have to be applied regularly at times that do not interfere with the dosing schedule for medication, once-daily dosing is a great advantage when encouraging patients to comply with the regimen.<sup>42,47</sup> MPA has a very rapid onset of activity, offering the potential to curtail duration of treatment; the low incidence of systemic side-effects may also appeal to patients with 'corticosteroid phobia'.<sup>14,38–43,49</sup> Finally, MPA is available in a wide range of formulations, including two ointments, a cream, a lotion and a milk, of equal efficacy that suit the needs of different patient age, skin condition, location of lesions and disease severity.<sup>39,40,49</sup>

### Safety of MPA in AD

A number of studies involving animal models, healthy volunteers and patients have demonstrated that the incidence and severity of adverse effects with MPA are significantly lower than that with other corticosteroids of comparable efficacy, and are similar to those of some less potent corticosteroids.<sup>46,48–50</sup>

### Short-term local events

MPA is very well tolerated in the majority of patients: the incidence of adverse events is around 5%.<sup>36</sup> Adverse events are almost always mild-to-moderate in severity,<sup>39,40</sup> and rarely result in treatment discontinuation.<sup>40,48,50</sup> The most common local adverse events are mild erythema, sensation of burning, dryness, scaling and rash.<sup>39,40</sup> These result from non-specific irritation of the skin and may be attributed to excipients in the formulation rather than to MPA.<sup>50</sup>

### Longer-term local events

The long-term safety of MPA has been studied in animals, healthy volunteers and in clinical studies.

**Animal models.** Experiments in animal models indicate that the atrophogenic potential of MPA is low.<sup>36,51</sup> In naked Wistar rats, MPA caused greater skin thinning than did vehicle, but significantly less ( $P < 0.05$ ) than MM after 19 days' treatment.<sup>52</sup> The incidence of telangiectasias was also significantly less ( $P < 0.05$ ) with MPA than with MM.

**Healthy volunteers.** The atrophogenic potential of MPA (0.1%) in cream and ointment preparations under occlusive conditions was found to be significantly less than that of clobetasol 17-propionate or MM<sup>46,50</sup> but similar to that of betamethasone 17-valerate (BMV).<sup>36,50</sup> Under clinical conditions, treatment with MPA (0.1%) cream and fatty ointment twice daily for 8 weeks resulted in a greater incidence of telangiectasias than with vehicle alone but a lower incidence than with BMV<sup>50</sup> or MM.<sup>46</sup> Most (80%)

telangiectasias resulting from MPA treatment were rated as 'slight'.<sup>46</sup> Daily MPA treatments over an 8-week period reduced skin thickness (as measured by ultrasound imaging); this reduction was slightly more noticeable with the fatty ointment.<sup>50</sup> Treatment with MPA (0.1%) cream affected skin thickness less than did MPA (0.1%) fatty ointment or either formulation of BMV. There were no differences observed between the cream and fatty ointment formulations of MPA in terms of atrophogenic potential<sup>50</sup> or incidences of telangiectasias and skin thinning.<sup>51</sup>

**Clinical studies.** In pooled study results from 1145 patients with AD, only one heavily pretreated patient had signs of skin atrophy.<sup>40</sup> In pooled results from more than 600 patients with AD, two patients experienced atrophy and one developed telangiectasias – although in one case each, the atrophy and telangiectasias appeared within days of starting treatment, suggesting that treatment was unmasking pre-existing conditions.<sup>50</sup>

The range and severity of skin irritation events were similar between patients treated with long-term maintenance therapy (two doses per week) and acute therapy, but the incidence of events was higher in the MPA group (15%), although not higher than with emollient alone (24%).<sup>44</sup>

### Systemic events

Absorption of corticosteroids into the systemic circulation can cause a number of specific and non-specific symptoms. Non-specific symptoms include hyperglycaemia, hypertension, leucocytosis and potassium and sodium shifts.<sup>5</sup> The rapid onset of action of MPA, followed by inactivation of its metabolites following absorption, confers a lower risk of unwanted systemic effects. No non-specific systemic events were observed in patients treated with MPA (0.1%) ointment for 3 months.<sup>50</sup>

The most concerning systemic effect of corticosteroids is suppression of the hypothalamic-pituitary-adrenal (HPA) axis. In humans, this is measured as reduction in serum cortisol concentrations, and anomalies in the circadian rhythm. Degree of adrenal suppression is dependent on duration of treatment, drug potency, area of skin covered and condition of the skin.<sup>31</sup>

**Animal models.** In rats, MPA did not suppress cortisol, as assessed by measuring the weight of the thymus, even after 43 days of treatment.<sup>36</sup>

**Healthy volunteers.** In one small study using occlusive treatment with MPA (0.1%) ointment over 60% of the body surface,<sup>46</sup> 5 of 10 healthy volunteers experienced changes neither in serum cortisol levels nor in circadian rhythm after 6 days, two had suppressed circadian rhythm but no cortisol changes and the remainder had depressed cortisol levels and altered circadian rhythm.

In another study in 100 healthy volunteers using 40 g topical MPA (0.1%) applied daily over 60% of the body surface, with skin

dressed with cotton or occluded for 22/24 h per day, no changes were observed over 8 days.<sup>49,50</sup>

**Clinical studies.** Four adult patients with AD involving 40–60% of the skin surface treated with 30 g MPA (0.1%) fatty ointment (15 g twice daily) for 7 days similarly experienced no effects on the HPA axis. A long-term study of MPA fatty ointment (1–3 times daily application) in chronic dermatoses showed no evidence of suppressed endogenous cortisol secretion in 45 adult patients over a 4-month period.<sup>50</sup>

### Safety in children

AD is more prevalent in children than in adults. Children's smaller size, increased vulnerability of the skin (particularly in infants) and the potential necessity for long-term treatment means that the safety of medications is of greater concern in this population. Systemic effects are of most concern because over-use can result in restricted growth and development in children.<sup>41</sup> Nevertheless, the effects of topical steroids are marginal, in comparison with the influence of extent of the disease.<sup>53</sup>

Several formulations of MPA, including a milk, are indicated for use in young children. In clinical trials, no adverse events were recorded in children younger than 4 years of age who received once-daily applications of the milk formulation of MPA for up to 14 days.<sup>41</sup> In a range of trials ( $N = 213$ ) with children aged 4 months to 15 years with mild, moderate or severe AD treated once-daily with MPA (0.1%) ointment for up to 21 days, adverse events were mostly absent. Some cases of mild burning sensation were recorded and very few children experienced infectious skin diseases.<sup>48,54,55</sup> There were no discontinuations because of adverse events in these trials. Cortisol levels remained at baseline concentrations in children treated with MPA for 1 week.<sup>48</sup>

### Conclusions

While emollients are an important basis for treatment in AD, management of acute exacerbations requires the additional use of anti-inflammatory therapy to treat flares and alleviate symptoms such as itching. Corticosteroids have been the gold standard treatment for AD for over 50 years, providing rapid relief of symptoms and a reduction in inflammation. The most recent generation of corticosteroids balances high potency with low incidence of local adverse events and absence of systemic events. MPA – with increased lipophilicity and binding affinity for the GR – typifies this new, optimized generation. Its local activation in the skin, followed by rapid inactivation of metabolites, minimizes the risk of systemic adverse effects. The rapid onset of activity of MPA, high efficacy and potency and very low incidence of adverse events in patients treated with a range of formulations of MPA (0.1%), together with availability of once-daily dosing, a major benefit for patient acceptability and compliance with treatment, make MPA an effective and well-tolerated choice for a wide range of patients with AD. In addition, the recently proposed intermittent use of

topical corticosteroids – proactive treatment – with a favourable safety profile such as MPA provides a novel, safe and effective approach to control AD.

### Acknowledgements

Prof. Luger would like to thank Jane Tricker and Marian East of MedSense Ltd for editorial assistance in the preparation of this manuscript.

### References

- Ross T, Ross G, Varigos G. Eczema: practical management issues. *Aust Fam Physician* 2005; **34**: 319–324.
- Akdis CA, Akdis M, Bieber T *et al.* Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. *Allergy* 2006; **61**: 969–987.
- Szczepanowska J, Reich A, Szepietowski JC. Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative study. *Pediatr Allergy Immunol* 2008; **19**: 614–618.
- Daniels R, Knie U. Galenics of dermal products – vehicles, properties and drug release. *J Deutsch Dermatol Ges* 2007; **5**: 367–383.
- Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. *J Am Acad Dermatol* 2006; **54**: 1–15.
- Wiedersberg S, Leopold CS, Guy RH. Bioavailability and bioequivalence of topical glucocorticoids. *Eur J Pharm Biopharm* 2008; **68**: 453–466.
- Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. *Am J Clin Dermatol* 2002; **3**: 47–58.
- Täuber U. Dermacorticosteroids: structure, activity, pharmacokinetics. *Eur J Dermatol* 1994; **4**: 419–429.
- Woźniacka A, Sysa-Jędrzejowska A. Topical steroids – a new approach after 50 years. *Med Sci Monit* 2001; **7**: 539–544.
- Luger T, Loske K, Elsner P *et al.* Topical skin therapy with glucocorticosteroids – therapeutic index. *J Deutsch Dermatol Ges* 2004; **7**: 629–634.
- Fokkens WJ, Godthelp T, Holm AF, Klein-Jan A. Local corticosteroid treatment: the effect on cells and cytokines in nasal allergic inflammation. *Am J Rhinol* 1998; **12**: 21–26.
- Almawi W, Melemedjian O, Rieder M. An alternate mechanism of glucocorticoid anti-proliferative effect: promotion of a Th2 cytokine-secreting profile. *Clin Transplant* 1999; **13**: 365–374.
- Nawata H, Okabe T, Yanase T, Nomura M. Mechanism of action and resistance to glucocorticoid and selective glucocorticoid receptor modulator to overcome glucocorticoid-related adverse effects. *Clin Experiment Allergy Rev* 2008; **8**: 53–56.
- Haria M, Balfour JA. Methylprednisolone aceponate. A review of its pharmacological properties and therapeutic potential in the topical treatment of eczema. *Clin Immunother* 1995; **3**: 241–253.
- Guyre PM, Girard MT, Morganelli PM, Manganiello PD. Glucocorticoid effects on the production and actions of immune cytokines. *J Steroid Biochem* 1988; **30**: 89–93.
- Biola A, Pallardy M. Mode of action of glucocorticoids. *Presse Med* 2000; **29**: 215–223.
- Falus A, Biró J, Rákász E. Cytokine networks and corticosteroid receptors. *Ann N Y Acad Sci* 1995; **762**: 71–77.
- Valencia IC, Kerdel FA. Topical corticosteroids. In: Wolff K, Goldsmith LA, Katz SI *et al.*, eds. *Fitzpatrick's Dermatology in General Medicine*, 7th edn. McGraw Hill, New York, NY, 2007: 2102–2106. Chapter 216.
- Blackwell GJ, Carnuccio R, Di Rosa M *et al.* Macro cortin: a polypeptide causing the anti-phospholipase effect of glucocorticoids. *Nature* 1980; **287**(5778): 147–149.

- 20 Hoetzenecker W, Meingassner JG, Ecker R *et al.* Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. *J Invest Dermatol* 2004; **122**: 673–684.
- 21 Kalthoff FS, Chung J, Musser P, Stuetz A. Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. *Clin Exp Immunol* 2003; **133**: 350–359.
- 22 Schwiebert LM, Beck LA, Stellato C *et al.* Glucocorticosteroid inhibition of cytokine production: relevance to anti-allergic actions. *J Allergy Clin Immunol* 1996; **97**(1 Pt 2): 143–152.
- 23 Boschetto P, Rogers DF, Fabbri LM, Barnes PJ. Corticosteroid inhibition of airway microvascular leakage. *Am Rev Respir Dis* 1991; **143**: 605–609.
- 24 Haapasari KM, Risteli J, Koivukangas V, Oikarinen A. Comparison of the effect of hydrocortisone, hydrocortisone-17-butyrate and betamethasone on collagen synthesis in human skin *in vivo*. *Acta Derm Venereol* 1995; **75**: 269–271.
- 25 Lagos BR, Maibach HI. Frequency of application of topical corticosteroids: an overview. *Br J Dermatol* 1998; **139**: 763–766.
- 26 Mori M, Pimpinelli N, Giannotti B. Topical corticosteroid and unwanted local effects. *Drug Saf* 1994; **10**: 406–412.
- 27 Kao JS, Fluhr JW, Man MQ *et al.* Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. *J Invest Dermatol* 2003; **120**: 456–464.
- 28 Jensen JM, Pfeiffer S, Witt M *et al.* Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. *J Allerg Clin Immunol* 2009; **123**: 1124–1133.
- 29 Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. *Br J Dermatol* 2000; **142**: 931–936.
- 30 Lamberts SWJ, Huizenga ATM, de Lange P *et al.* Clinical aspects of glucocorticoid sensitivity. *Steroids* 1996; **61**: 157–160.
- 31 Zentel HJ, Töpert M. Preclinical evaluation of a new topical corticosteroid methylprednisolone aceponate. *J Eur Acad Dermatol Venereol* 1994; **3**(Suppl 1): S32–S38.
- 32 Dyes PJ, Marks R. An appraisal of the methods used in the assessment of atrophy from topical corticosteroids. *Br J Dermatol* 1979; **101**: 599–609.
- 33 Stenmovic DU. Corticosteroid-induced atrophy of the skin with telangiectasia: a clinical and experimental study. *Br J Dermatol* 1972; **87**: 548–556.
- 34 Greaves MW, Gatti S. The use of glucocorticoids in dermatology. *J Dermatol Treat* 1999; **10**: 83–91.
- 35 Täuber U. Pharmacokinetics and 'bioactivation' of MPA. *J Eur Acad Dermatol Venereol* 1994; **3**(Suppl 1): S23–S31.
- 36 Zaumseil R-P, Kecskes A, Täuber U, Topert M. Methylprednisolone aceponate (MPA) - a new therapeutic for eczema: a pharmacological overview. *J Dermatol Treat* 1992; **3**(Suppl 2): 3–7.
- 37 Täuber U. Skin pharmacokinetics of a new topical glucocorticosteroid MPA. In: Scott RC *et al.*, eds. *Prediction of Percutaneous Penetration, Methods, Measurements, Modelling: Proceedings of a Conference held in April 1989*. IBS Technical Services, London, 1990: 37–48.
- 38 Albrecht G. Clinical comparison of methylprednisolone aceponate and prednicarbate in chronic eczema. *J Eur Acad Dermatol Venereol* 1994; **3**(Suppl 1): S42–S48.
- 39 Mensing H, Lorenz B. Experience with methylprednisolone aceponate (MPA) in patients suffering from acute and chronic eczema – results of a large observational study. *Z Hautkrankh* 1998; **73**: 281–285.
- 40 Fritsch P. Clinical experience with methylprednisolone aceponate (MPA) in eczema. *J Dermatol Treat* 1992; **3**(Suppl 2): 17–19.
- 41 Casano AV, Cavallé JR. The milk formulation in topical corticotherapy: outcomes in children with atopic dermatitis. *Monografía de Dermatología* 2002; **15**: 399–408.
- 42 Bieber T, Vick K, Fölster-Holst R *et al.* Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. *Allergy* 2007; **62**: 184–189.
- 43 Sonnichsen N, Zaumseil R-P. Efficacy and tolerability of methylprednisolone aceponate solution in eczematous diseases of the hairy scalp. *Dermatology* 1999; **5**: 317–324.
- 44 Peserico A, Städtler G, Sebastian M *et al.* Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. *Br J Dermatol* 2008; **158**: 801–807.
- 45 Reitamo S, Allsopp R, Naidoo S. Treatment of moderate and severe atopic dermatitis in children with twice weekly tacrolimus 0.03% ointment (Abstract P503). *J Am Acad Dermatol* 2010; **62**(3): AB10.
- 46 Kecskés A, Heger-Mahn D, Kuhlmann RK, Lange L. Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointments with equal anti-inflammatory activity. *J Am Acad Dermatol* 1993; **29**: 576–580.
- 47 Haneke E. The treatment of atopic dermatitis with methylprednisolone aceponate (MPA), a new topical corticosteroid. *J Dermatol Treat* 1992; **3**(Suppl 2): 13–15.
- 48 Rampini E. Methylprednisolone aceponate (MPA) - use and clinical experience in children. *J Dermatol Treat* 1992; **3**(Suppl 2): 27–29.
- 49 Zaumseil R-P, Fuhrmann H, Kecskés A *et al.* Methylprednisolone aceponate (Advantan) an effective topical corticoid therapy with few side effects. In: Macher E, Kolde G, Brucker EB, eds. *Jahrbuch der Dermatologie*. Biermann-Verlag, Zülpich, Germany, 1992/93:247–263.
- 50 Ortonne J-P. Safety aspects of topical methylprednisolone aceponate (MPA) treatment. *J Dermatol Treat* 1992; **3**(Suppl 2): 21–25.
- 51 Ortonne J-P. Skin atrophogenic potential of methylprednisolone aceponate (MPA). *J Eur Acad Dermatol Venereol* 1994; **3**(Suppl 1): S13–S18.
- 52 Mirshahpanah P, Döcke W-D, Merbold U *et al.* Superior nuclear receptor selectivity and therapeutic index of methylprednisolone aceponate versus mometasone furoate. *Exp Dermatol* 2007; **16**: 753–761.
- 53 Massarano AA, Hollis S, Devlin J *et al.* Growth in atopic eczema. *Arch Dis Child* 1993; **68**: 677–679.
- 54 Alchorne MM, Da CP, Cestari S *et al.* A multicenter, comparative, open-labelled, randomized study of tolerability and efficacy of methylprednisolone aceponate and mometasone furoate in children from 2 to 14 years of age suffering from atopic dermatitis. *Ped Mod* 2003; **39**: 275–280.
- 55 Korotky NG, Taganov AV, Shimanovsky NL. Use of Advantan in the treatment of atopic dermatitis in children. *Pediatriya* 2000; **5**: 75–78.